Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.
Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.
Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.
Tiziana Life Sciences (NASDAQ:TLSA) announced an interview with CEO Dr. Kunwar Shailubhai discussing the therapeutic potential of Foralumab for COVID-19. The nasal administration of Foralumab demonstrated nearly double the improvement in lung CT scans compared to a control group. This proprietary nasal delivery aims to modulate immunity and alleviate symptoms, especially with emerging COVID-19 variants in the UK, South Africa, and Brazil. Tiziana is also developing Foralumab for liver diseases and has ongoing projects targeting various autoimmune conditions.
On January 27, 2021, Tiziana Life Sciences (Nasdaq: TLSA) announced the filing of a "universal" shelf registration statement with the SEC for up to $250 million in securities. This move allows for efficient access to U.S. capital markets. The registration includes a preliminary prospectus for an "at-the-market" sales agreement with B. Riley Securities, enabling the potential sale of up to $100 million in American Depositary Shares. Notably, Tiziana has no immediate plans for any offerings under this registration.
Tiziana Life Sciences announced that its CEO and CSO, Dr. Kunwar Shailubhai, will host a fireside chat on January 21, 2021, at 3 PM ET / 8 PM GMT. The discussion will provide updates on the company's ongoing developments, particularly in oncology and inflammation. Tiziana is advancing therapeutics such as Foralumab, a fully human anti-CD3 monoclonal antibody, and its IL6R monoclonal antibody for treating COVID-19. Interested parties can join the webcast through a provided link.
Tiziana Life Sciences has announced its transition from AIM to the Main Market of the London Stock Exchange, effective January 21, 2021. Following the last trading day on AIM on January 20, the Company’s Ordinary Shares will be admitted to the Official List and commence trading on the Main Market. Tiziana focuses on developing innovative treatments for oncology, inflammation, and infectious diseases, with ongoing Phase 2 studies for its uniquely human anti-CD3 monoclonal antibody, Foralumab, targeting conditions such as Crohn's Disease and multiple sclerosis.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the appointment of Dr. Neil Graham as Chief Medical Officer. Dr. Graham has extensive experience in medicines development, having previously held roles at Regeneron and Vertex. He played a key role in the launch of blockbuster drugs like Dupixent. Tiziana's unique monoclonal antibody platform for autoimmune diseases could significantly impact the treatment landscape. The company is advancing clinical studies for Foralumab, an innovative monoclonal antibody addressing various autoimmune conditions.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced its participation in the J.P. Morgan 39th Annual Healthcare Conference 2021. CEO Dr. Kunwar Shailubhai expressed excitement about presenting significant advancements, including topline data from a COVID-19 trial expected this month and anticipated launches of multiple Phase 2 trials in 2021. The company is exploring Foralumab, a fully human anti-CD3 monoclonal antibody, for various autoimmune diseases and aims to address IL6-induced inflammation in COVID-19 patients. For more details, visit Tiziana's website.
Tiziana Life Sciences (NASDAQ: TLSA) announced its participation in Biotech Showcase 2021, providing on-demand presentations for attendees. Dr. Kunwar Shailubhai, CEO, stated that topline data from a COVID-19 trial is expected this month, with several Phase 2 trial launches planned for 2021. With the potential application of Foralumab in various autoimmune diseases, the company aims to achieve significant milestones impacting its valuation. Biotech Showcase serves as a networking platform for life science professionals and investors, promoting innovations in drug discovery.
Tiziana Life Sciences (Nasdaq: TLSA) has completed a clinical study in Brazil on nasally administered Foralumab for COVID-19 patients. The trial showed positive anecdotal feedback from patients, highlighting rapid improvement in smell sensation, a common COVID-19 symptom. The study involved 39 patients with moderate to severe COVID-19, assessing safety and efficacy against the disease. Topline data is expected in January 2021, with implications for treating coronaviruses as well as potential applications in other diseases. This novel approach aims to enhance the immune response against COVID-19 variants.
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) announces its admission of ordinary shares to the Official List of the FCA and the Main Market of the London Stock Exchange. The prospectus for this listing was approved on December 18, 2020. Key dates include the last day of trading on AIM on January 20, 2021, with delisting and trading on the Main Market commencing on January 21, 2021, at 8:00 am. Tiziana is focused on innovative therapeutics for oncology and other diseases, including advancing clinical studies for its unique fully human anti-CD3 monoclonal antibody for various conditions.
Tiziana Life Sciences (Nasdaq: TLSA) has announced its application for a standard listing on the Official List of the FCA and trading admission on the London Stock Exchange's Main Market. The company will cancel AIM trading, effective January 21, 2021, and will not issue new shares during this transition. The prospectus is expected to be published on December 18, 2020. Tiziana focuses on innovative therapeutics for oncology, inflammation, and infectious diseases, with phase 2 studies planned for its drug, foralumab.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
